United States · Venture startup

Who invested in Tympanogen

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$1.2Mraised across 1 round since 2025, from 1 source

Latest round
Venture, $1.2MMar 2025
Investors
2
See who backed them

The rounds

  1. Mar 2025
    Venture$1.2M

    Source recordedSEC filing: $1.2M sold, first sale Feb 2025

Founders and team

From Tympanogen's own website: 2 on the team.

  • Tim SaumierPresident, TYGES International
  • Scientist IBoard of Directors

AdvisersJason Whiting

Everyone who backed them

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Tympanogen as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

VisionTech PartnersAngel networkPer its own site
ShockVenturesVC firmPer its own site

Quick answers about Tympanogen

Who invested in Tympanogen?

Tympanogen's investors include MassChallenge and Virginia Innovation Partnership Corporation.

How much has Tympanogen raised?

Tympanogen has raised $1.2M across 1 round since 2025.

When did Tympanogen last raise?

Tympanogen's most recent round was a Venture of $1.2M in Mar 2025.

What was Tympanogen's biggest round?

Its most recent round, $1.2M in Mar 2025, is also its largest on record.

Who backed Tympanogen first?

Tympanogen's first round on record, in Mar 2025, was backed by MassChallenge and Virginia Innovation Partnership Corporation.

What stage is Tympanogen at?

Tympanogen's latest named round is a Venture, in Mar 2025.

Where is Tympanogen based?

Tympanogen is based in the United States.

Companies like Tympanogen

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.